Wide Ranks

ANTX

AN2 Therapeutics, Inc.

1.37

Top Statistics
Market Cap 40 M Forward PE -1.18 Revenue Growth 0.00 %
Current Ratio 10.61 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 104 M Total Cash Per Share 3.50 Total Debt
Total Debt To Equity Current Ratio 10.61 Book Value Per Share 4.19
All Measures
Short Ratio 82.00 % Message Board Id finmb_645116379 Shares Short Prior Month 188480
Return On Equity -0.6948 City Menlo Park Uuid fa00a21b-8695-3bf1-94dc-fb69ab804327
Previous Close 1.39 First Trade Date Epoch Utc 1 B Book Value 4.19
Beta -0.2230 Volume 575158 Price To Book 0.3267
Fifty Two Week Low 0.8700 Total Cash Per Share 3.50 Shares Short Previous Month Date 1 B
Target Median Price 2.00 Max Age 86400 Recommendation Mean 3.20
Sand P52 Week Change 0.3133 Target Mean Price 2.67 Net Income To Common -64657000
Short Percent Of Float 0.0069 Implied Shares Outstanding 29 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 104 M Next Fiscal Year End 1 B Held Percent Insiders 0.2164
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.39 Target Low Price 1.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.09 Open 1.38 Free Cashflow -36395876
State CA Dividend Yield 0.00 % Return On Assets -0.4289
Time Zone Short Name EST Trailing Eps -1.99 Day Low 1.34
Address1 1800 El Camino Real Shares Outstanding 29 M Price Hint 4
Target High Price 5.00 Website https://www.an2therapeutics.com 52 Week Change -0.9220
Average Volume 475360 Forward Eps -1.16 Recommendation Key hold
Compensation As Of Epoch Date 1 B Quick Ratio 1035.30 % Is_sp_500 False
Regular Market Day High 1.45 Profit Margins 0.00 % Fifty Two Week High 22.22
Day High 1.45 Shares Short 133574 Regular Market Open 1.38
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0045 Operating Cashflow -60845000 Currency USD
Time Zone Full Name America/New_York Market Cap 40 M Is_nasdaq_100 False
Zip 94027 Quote Type EQUITY Industry Biotechnology
Long Name AN2 Therapeutics, Inc. Regular Market Day Low 1.34 Held Percent Institutions 0.5231
Current Price 1.37 Address2 Suite D Financial Currency USD
Current Ratio 10.61 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 11 M Two Hundred Day Average 2.02
Enterprise Value -74697568 Forward PE -1.18 Regular Market Volume 575158
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.

It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease.

The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials.

It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases.

The company was incorporated in 2017 and is headquartered in Menlo Park, California.